News Center
Details
Yichang Renfu Pharmaceutical’s Bupropion Hydrochloride Extended-Release Tablets (XL) Approved for Marketing in Canada
Release time:
2026-01-12 10:54
Source:
Recently, Yichang Renfu Pharmaceutical’s Bupropion Hydrochloride Extended-Release Tablets (XL) received a drug marketing authorization approved and issued by Health Canada. The approved indications are to relieve symptoms of major depressive disorder and to prevent seasonal episodes of major depressive disorder during autumn and winter. The tablet strengths are 150 mg and 300 mg.
Bupropion hydrochloride is an aminoketone antidepressant that functions as a norepinephrine-dopamine reuptake inhibitor (NDRI). It exerts its antidepressant effects by inhibiting the reuptake of norepinephrine and dopamine. While effectively alleviating depressive symptoms, this medication is less likely to cause common side effects such as weight gain, sexual dysfunction, or drowsiness, thereby demonstrating a distinct advantage in terms of safety. Its extended-release tablet formulation (XL) further enhances patient adherence and tolerability by providing a steady and controlled release of the drug.
The sustained-release bupropion hydrochloride tablets (XL) are Yichang Humanwell Pharmaceutical’s first product to be independently submitted for and approved in Canada, providing product support for the company’s entry into the North American market and marking another significant breakthrough in the company’s internationalization strategy.
Trending News
Corporate culture
Make drug launches safer and faster, and ensure the tree of life remains evergreen.
Learn moreContact Us
Business customer service
-
Telephone：:+86-027-86506632
Human Resources Department
Address: No.98 shendun 2nd Road, Donghu New Technology Development Zone, Wuhan
Official wechat
Copyright: Wuhan humanwell likang pharmaceutical co.,ltd